Caroline Graff

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7156915/publications.pdf

Version: 2024-02-01

191 papers	18,147 citations	47006 47 h-index	16650 123 g-index
214 all docs	214 docs citations	214 times ranked	23021 citing authors

#	Article	IF	Citations
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
2	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates Aî², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
3	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	10.2	1,242
4	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
5	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
6	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	10.2	432
7	Impaired insulin secretion and Î²-cell loss in tissue-specific knockout mice with mitochondrial diabetes. Nature Genetics, 2000, 26, 336-340.	21.4	417
8	Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nature Genetics, 1999, 21, 133-137.	21.4	393
9	Modulation of the endoplasmic reticulumâ€“mitochondria interface in Alzheimerâ€™s disease and related models. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7916-7921.	7.1	381
10	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
11	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	12.8	263
12	Increased mitochondrial mass in mitochondrial myopathy mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15066-15071.	7.1	262
13	A Panâ€<scp>E</scp>uropean Study of theC9orf72Repeat Associated with<scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	2.5	247
14	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 922-936.	7.6	235
15	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
16	Resolution of inflammation is altered in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 40.	0.8	208
17	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	3.7	207
18	Amyloid-Î² Peptide Induces Mitochondrial Dysfunction by Inhibition of Preprotein Maturation. Cell Metabolism, 2014, 20, 662-669.	16.2	176

#	Article	IF	Citations
19	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
20	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
21	The Obesity Related Gene, FTO, Interacts with APOE, and is Associated with Alzheimer's Disease Risk: A Prospective Cohort Study. Journal of Alzheimer's Disease, 2011, 23, 461-469.	2.6	163
22	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
23	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	3.1	151
24	Association of TMEM106B Gene Polymorphism With Age at Onset in Granulin Mutation Carriers and Plasma Granulin Protein Levels. Archives of Neurology, 2011, 68, 581-6.	4.5	148
25	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
26	Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology, 2012, 79, 229-236.	1.1	138
27	PSEN1Î”E9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia. Stem Cell Reports, 2019, 13, 669-683.	4.8	132
28	AÎ²43 is more frequent than AÎ²40 in amyloid plaque cores from Alzheimer disease brains. Journal of Neurochemistry, 2009, 110, 697-706.	3.9	129
29	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
30	Genetic effects on old-age cognitive functioning: A population-based study.. Psychology and Aging, 2013, 28, 262-274.	1.6	111
31	Early astrocytosis in autosomal dominant Alzheimerâ€™s disease measured in vivo by multi-tracer positron emission tomography. Scientific Reports, 2015, 5, 16404.	3.3	110
32	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
33	Effects of vascular risk factors and APOE Îµ4 on white matter integrity and cognitive decline. Neurology, 2015, 84, 1128-1135.	1.1	105
34	Structural heterogeneity and intersubject variability of AÎ² in familial and sporadic Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E782-E791.	7.1	105
35	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
36	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93

#	Article	IF	Citations
37	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
38	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
39	REST suppression mediates neural conversion of adult human fibroblasts via microRNAâ€dependent and â€independent pathways. EMBO Molecular Medicine, 2017, 9, 1117-1131.	6.9	87
40	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 213-224.	7.7	83
41	APOE-related mortality: Effect of dementia, cardiovascular disease and gender. Neurobiology of Aging, 2009, 30, 1545-1551.	3.1	74
42	The gene for Best's macular dystrophy is located at 11q13 in a Swedish family. Clinical Genetics, 1992, 42, 156-159.	2.0	70
43	The Pathogenic AÎ²43 Is Enriched in Familial and Sporadic Alzheimer Disease. PLoS ONE, 2013, 8, e55847.	2.5	66
44	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	2.7	63
45	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
46	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	7.6	55
47	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	1.9	55
48	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimerâ€™s disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
49	The benefits of staying active in old age: Physical activity counteracts the negative influence of PICALM, BIN1, and CLU risk alleles on episodic memory functioning.. Psychology and Aging, 2014, 29, 440-449.	1.6	52
50	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.1	52
51	A DNA Methylation Study of the Amyloid Precursor Protein Gene in Several Brain Regions from Patients with Familial Alzheimer Disease. Journal of Neurogenetics, 2010, 24, 179-181.	1.4	48
52	Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiology of Aging, 2011, 32, 1388-1399.	3.1	48
53	Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Annals of Clinical and Translational Neurology, 2018, 5, 583-597.	3.7	48
54	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47

#	Article	IF	Citations
55	A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14854-14859.	7.1	45
56	Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE. Neurobiology of Aging, 2007, 28, 1374-1380.	3.1	43
57	Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model. Neurobiology of Aging, 2011, 32, 280-292.	3.1	42
58	Identification and description of three families with familial Alzheimer disease that segregate variants in the SORL1 gene. Acta Neuropathologica Communications, 2017, 5, 43.	5.2	42
59	Novel <scp>CSF</scp> biomarkers in genetic frontotemporal dementia identified by proteomics. Annals of Clinical and Translational Neurology, 2019, 6, 698-707.	3.7	42
60	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Neurology, 2020, 94, e2026-e2036.	1.1	42
61	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
62	Association study of two genetic variants in mitochondrial transcription factor A (TFAM) in Alzheimer's and Parkinson's disease. Neuroscience Letters, 2007, 420, 257-262.	2.1	41
63	Comparison of arterial spin labeling registration strategies in the multiâ€center GENetic frontotemporal dementia initiative (GENFI). Journal of Magnetic Resonance Imaging, 2018, 47, 131-140.	3.4	41
64	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	7.6	41
65	Genetic association to the amyloid plaque associated protein gene COL25A1 in Alzheimer's disease. Neurobiology of Aging, 2010, 31, 409-415.	3.1	40
66	Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Neurobiology of Aging, 2012, 33, 831.e11-831.e19.	3.1	40
67	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	3.1	40
68	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
69	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	3.7	39
70	Amyloid Î²-Peptide Increases Mitochondria-Endoplasmic Reticulum Contact Altering Mitochondrial Function and Autophagosome Formation in Alzheimerâ€™s Disease-Related Models. Cells, 2020, 9, 2552.	4.1	39
71	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
72	Confirmation of linkage to 1q21-31 in a Danish autosomal dominant juvenile-onset glaucoma family and evidence of genetic heterogeneity. Human Genetics, 1995, 96, 285-9.	3.8	35

#	Article	IF	Citations
73	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	3.1	34
74	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	6.2	34
75	The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of AÎ² in different brain regions. European Journal of Human Genetics, 2010, 18, 1202-1208.	2.8	33
76	The influence of APOE and TOMM40 polymorphisms on hippocampal volume and episodic memory in old age. Frontiers in Human Neuroscience, 2013, 7, 198.	2.0	33
77	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	4.2	33
78	Online information and support for carers of people with youngâ€onset dementia: A multiâ€site randomised controlled pilot study. International Journal of Geriatric Psychiatry, 2019, 34, 1455-1464.	2.7	33
79	The effects of different familial Alzheimerâ€™s disease mutations on APP processing in vivo. Alzheimer's Research and Therapy, 2017, 9, 9.	6.2	32
80	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 55.	4.8	32
81	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.8	31
82	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
83	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain, 2023, 146, 321-336.	7.6	30
84	Characterizing the Clinical Features and Atrophy Patterns of MAPT -Related Frontotemporal Dementia With Disease Progression Modeling. Neurology, 2021, 97, e941-e952.	1.1	29
85	Fine Mapping of Best's Macular Dystrophy Localizes the Gene in Close Proximity to but Distinct from the D11S480/ROM1 Loci. Genomics, 1994, 24, 425-434.	2.9	28
86	Novel TARDBP mutations in Nordic ALS patients. Journal of Human Genetics, 2012, 57, 316-319.	2.3	28
87	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. Journal of Alzheimer's Disease, 2018, 65, 1-16.	2.6	28
88	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
89	The Bri2 and Bri3 BRICHOS Domains Interact Differently with AÎ²42 and Alzheimer Amyloid Plaques. Journal of Alzheimer's Disease Reports, 2018, 2, 27-39.	2.2	27
90	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27

#	Article	IF	Citations
91	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
92	Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1393-1402.	2.6	26
93	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
94	Altered enzymatic activity and allele frequency of OMI/HTRA2 in Alzheimer's disease. FASEB Journal, 2011, 25, 1345-1352.	0.5	25
95	Mitochondrial dysfunction in a transgenic mouse model expressing human amyloid precursor protein (<scp>APP</scp>) with the Arctic mutation. Journal of Neurochemistry, 2016, 136, 497-502.	3.9	25
96	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	1.9	25
97	No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer's disease patients. Neuroscience Letters, 2003, 337, 111-113.	2.1	24
98	RHAPSODY â€“ Internet-based support for caregivers of people with young onset dementia: program design and methods of a pilot study. International Psychogeriatrics, 2016, 28, 2091-2099.	1.0	24
99	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
100	Rare Variants inPLD3Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	2.5	23
101	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. Epigenomics, 2015, 7, 533-537.	2.1	23
102	Education modulates brain maintenance in presymptomatic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1124-1130.	1.9	23
103	Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. Translational Neurodegeneration, 2020, 9, 27.	8.0	23
104	Mutation screening of patients with Alzheimer disease identifies APP locus duplication in a Swedish patient. BMC Research Notes, 2011, 4, 476.	1.4	21
105	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
106	No linkage to chromosome 14 in Swedish Alzheimer's disease families. Nature Genetics, 1993, 4, 218-219.	21.4	20
107	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	1.9	20
108	Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. Neurology, 2019, 93, e1699-e1706.	1.1	19

#	Article	IF	Citations
109	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
110	Complex genetic counselling and prenatal analysis in a woman with external ophthalmoplegia and deleted mtDNA. , 2000, 20, 426-431.		18
111	Expanded high-resolution genetic study of 109 Swedish families with Alzheimer's disease. European Journal of Human Genetics, 2008, 16, 202-208.	2.8	18
112	Genetic and biochemical studies of SNPs of the mitochondrial AÎ²-degrading protease, hPreP. Neuroscience Letters, 2010, 469, 204-208.	2.1	18
113	Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimerâ€™s Disease. Journal of the International Neuropsychological Society, 2017, 23, 195-203.	1.8	18
114	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	1.2	18
115	Mitochondrial diseases. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 715-728.	2.8	17
116	Biochemical Studies of Poly-T Variants in the Alzheimer's Disease Associated TOMM40 Gene. Journal of Alzheimer's Disease, 2012, 31, 527-536.	2.6	17
117	Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 17.	5.2	17
118	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	3.1	16
119	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	4.2	16
120	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimerâ€™s disease variants: AÎ²PParc and PSEN1DE9. Molecular Psychiatry, 2021, 26, 5609-5619.	7.9	16
121	The use of grid computing to drive data-intensive genetic research. European Journal of Human Genetics, 2007, 15, 694-702.	2.8	15
122	Refined genetic localization of the Best disease gene in 11q13 and physical mapping of linked markers on radiation hybrids. Human Genetics, 1997, 101, 263-270.	3.8	14
123	A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations. Brain Research, 2010, 1344, 185-191.	2.2	14
124	Neuropathological characterization of two siblings carrying the MAPT S305S mutation demonstrates features resembling argyrophilic grain disease. Acta Neuropathologica, 2014, 127, 297-298.	7.7	14
125	The meaning of living close to a person with Alzheimer disease. Medicine, Health Care and Philosophy, 2016, 19, 341-349.	1.8	14
126	Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family. , 2008, 4, 414-420.		13

#	Article	IF	Citations
127	Amyloid precursor protein accumulates in aggresomes in response to proteasome inhibitor. Neurochemistry International, 2012, 60, 533-542.	3.8	13
128	HHEX_23 AA Genotype Exacerbates Effect of Diabetes on Dementia and Alzheimer Disease: A Population-Based Longitudinal Study. PLoS Medicine, 2015, 12, e1001853.	8.4	13
129	Magnified effects of the COMT gene on white-matter microstructure in very old age. Brain Structure and Function, 2015, 220, 2927-2938.	2.3	12
130	Somatic mutation that affects transcription factor binding upstream of CD55 in the temporal cortex of a late-onset Alzheimer disease patient. Human Molecular Genetics, 2019, 28, 2675-2685.	2.9	12
131	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	1.9	12
132	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
133	Development of a sensitive trial-ready poly(GP) CSF biomarker assay forC9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	1.9	12
134	Interactive effects of KIBRA and CLSTN2 polymorphisms on episodic memory in old-age unipolar depression. Neuropsychologia, 2014, 62, 137-142.	1.6	11
135	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimer's Research and Therapy, 2018, 10, 45.	6.2	11
136	Conformationâ€specific antibodies against multiple amyloid protofibril species from a single amyloid immunogen. Journal of Cellular and Molecular Medicine, 2019, 23, 2103-2114.	3.6	11
137	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
138	Microstructural White Matter Properties Mediate the Association between APOE and Perceptual Speed in Very Old Persons without Dementia. PLoS ONE, 2015, 10, e0134766.	2.5	10
139	Ethical aspects of a predictive test for Huntingtonâ€™s Disease. Nursing Ethics, 2016, 23, 565-575.	3.4	10
140	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	1.9	10
141	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
142	Linkage to 20p13 including the ANGPT4 gene in families with mixed Alzheimer's disease and vascular dementia. Journal of Human Genetics, 2010, 55, 649-655.	2.3	9
143	Novel progranulin mutations with reduced serum-progranulin levels in frontotemporal lobar degeneration. European Journal of Human Genetics, 2013, 21, 1260-1265.	2.8	9
144	Findings from the Swedish Study on Familial Alzheimerâ€™s Disease Including the APP Swedish Double Mutation. Journal of Alzheimer's Disease, 2018, 64, S491-S496.	2.6	9

#	Article	IF	Citations
145	Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimerâ€™s Disease: A Pilot Study. Journal of Alzheimer's Disease, 2020, 76, 941-953.	2.6	9
146	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
147	The Effects of Gene Mutations onÂDefaultÂMode Network inÂFamilialÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 327-334.	2.6	8
148	Confirmation of high frequency of C9orf72 mutations in patients with frontotemporal dementia from Sweden. Neurobiology of Aging, 2019, 84, 241.e21-241.e25.	3.1	8
149	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. Neurobiology of Aging, 2021, 103, 158.e1-158.e5.	3.1	8
150	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	2.7	8
151	The Association Between APOE Îµ4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.	2.6	7
152	Ethical aspects of undergoing a predictive genetic testing for Huntington's disease. Nursing Ethics, 2013, 20, 189-199.	3.4	7
153	Generation of a human induced pluripotent stem cell line (LL008 1.4) from a familial Alzheimer's disease patient carrying a double KM670/671NL (Swedish) mutation in APP gene. Stem Cell Research, 2018, 31, 181-185.	0.7	7
154	Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes. Neurobiology of Aging, 2019, 82, 40-47.	3.1	7
155	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.1	7
156	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811.	7.6	7
157	Dataâ€driven staging of genetic frontotemporal dementia using multiâ€modal <scp>MRI</scp>. Human Brain Mapping, 2022, 43, 1821-1835.	3.6	7
158	Telomerase Gene (hTERT) and Survival: Results From Two Swedish Cohorts of Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 188-195.	3.6	5
159	Phenotypic variability and neuropsychological findings associated with C9orf72 repeat expansions in a Bulgarian dementia cohort. PLoS ONE, 2018, 13, e0208383.	2.5	5
160	Linkage to the 8p21.1 Region Including the CLU Gene in Age at Onset Stratified Alzheimer's Disease Families. Journal of Alzheimer's Disease, 2011, 23, 13-20.	2.6	5
161	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.1	5
162	Linkage Analysis of Autopsy-Confirmed Familial Alzheimer Disease Supports an Alzheimer Disease Locus in 8q24. Dementia and Geriatric Cognitive Disorders, 2011, 31, 109-118.	1.5	4

#	Article	IF	Citations
163	Partial tetrasomy 14 associated with multiple malformations. American Journal of Medical Genetics, Part A, 2013, 161, 1284-1290.	1.2	4
164	No common founder for C9orf72 expansion mutation in Sweden. Journal of Human Genetics, 2017, 62, 321-324.	2.3	4
165	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
166	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	6.2	4
167	Single-cell multimodal analysis in a case with reduced penetrance of Progranulin-Frontotemporal Dementia. Acta Neuropathologica Communications, 2021, 9, 132.	5.2	3
168	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	3.1	3
169	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	2.6	3
170	Effect of the Interplay Between Genetic and Behavioral Risks on Survival After Age 75. Journal of the American Geriatrics Society, 2016, 64, 2440-2447.	2.6	2
171	Overall and domainâ€specific life satisfaction when living with familial Alzheimer's disease risk: A quantitative approach. Australian Journal of Cancer Nursing, 2017, 19, 452-458.	1.6	2
172	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
173	Genetic mapping using fluorescent quantification of allele frequencies in pooled DNA loaded by solid support. Clinical Genetics, 1997, 51, 145-152.	2.0	1
174	[P1â€“437]: PRESYMPTOMATIC WHITE MATTER INTEGRITY LOSS IN FAMILIAL FRONTOTEMPORAL DEMENTIA IN THE GENETIC FRONTOTEMPORAL DEMENTIA INITIATIVE (GENFI) COHORT: A MULTIâ€CENTRE, CROSSâ€SECTIONAL DIFFUSION TENSOR IMAGING STUDY. Alzheimer's and Dementia, 2017, 13, P449.	0.8	1
175	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
176	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
177	The APOE Îµ4 Allele Affects Cognitive Functions Differently in Carriers of APP Mutations Compared to Carriers of PSEN1 Mutations in Autosomal-Dominant Alzheimerâ€™s Disease. Genes, 2021, 12, 1954.	2.4	1
178	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	1
179	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium. , 2015, 11, P253-P253.		0
180	P1â€025: Cerebral Perfusion as an Imaging Biomarker of Presymptomatic Genetic Frontotemporal Dementia: Preliminary Results from the Genetic Frontotemporal Dementia Initiative (GENFI). Alzheimer's and Dementia, 2016, 12, P409.	0.8	0

#	Article	IF	Citations
181	[P1â€“029]: IN GENETIC FRONTOTEMPORAL DEMENTIA, FUNCTIONAL NETWORK EFFICIENCY IS MAINTAINED UNTIL THE ONSET OF SYMPTOMS: EVIDENCE FOR FUNCTIONAL RESILIENCE TO STRUCTURAL CHANGE. Alzheimer's and Dementia, 2017, 13, P244.	0.8	0
182	[ICâ€03â€“04]: WHITE MATTER HYPERINTENSITIES IN GENETIC FRONTOTEMPORAL DEMENTIA: A GENFI STUDY. Alzheimer's and Dementia, 2017, 13, P9.	0.8	0
183	[P1â€“415]: IN GENETIC FRONTOTEMPORAL DEMENTIA, FUNCTIONAL NETWORK EFFICIENCY IS MAINTAINED UNTIL THE ONSET OF SYMPTOMS: EVIDENCE FOR FUNCTIONAL RESILIENCE TO STRUCTURAL CHANGE. Alzheimer's and Dementia, 2017, 13, P436.	0.8	0
184	O5â€01â€04: EARLY INFLAMMATION AND MICROSTRUCTURAL CORTICAL CHANGES IN FAMILIAL AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1639.	0.8	0
185	Plasma metabolomics of presymptomatic PSEN1â€H163Y mutation carriers: a pilot study. Annals of Clinical and Translational Neurology, 2021, 8, 579-591.	3.7	0
186	Pattern of progression in MAPTâ€related frontotemporal dementia: Results from the GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
187	Detecting clinical progression from abnormal regional brain volumes at baseline in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
188	A dataâ€driven disease progression model of fluid biomarkers in genetic FTD. Alzheimer's and Dementia, 2021, 17, .	0.8	0
189	Atrophy patterns in sporadic and genetic behavioral variant frontotemporal dementia reflect brain network architecture. Alzheimer's and Dementia, 2021, 17, .	0.8	0
190	A cognitive composite for genetic frontotemporal dementia: GENFIâ€cog. Alzheimer's and Dementia, 2021, 17, .	0.8	0
191	From brain volumes to subgroup classification in genetic mutation carriers for frontotemporal dementia: A cluster analysis in the GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.8	0